Springworks Therapeutics (SWTX) reported a Q4 net loss Thursday of $1.04 per share, narrowing from a net loss of $1.44 a year earlier.
Analysts polled by FactSet expected a loss of $0.71.
Net product revenue for the quarter ended Dec. 31 was $61.5 million. The previous year's numbers were not provided.
Three analysts surveyed by FactSet expected product revenue of $61.7 million.
The biopharmaceutical company held cash and cash equivalents worth $461.9 million as of Dec. 31. Two analysts polled by FactSet expected $466.8 million.
Shares of the company were up more than 10% in recent premarket activity.
Price: 61.80, Change: +6.07, Percent Change: +10.89
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。